A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
AstraZeneca
880 participants
Nov 18, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered intravenously (IV) on Day 1 of each 21-day cycle
Administered intravenously (IV) on Day 1 of each 21-day cycle
Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
Locations(301)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06692738